|
|||||
|
|
| Second-Line Treatment of Her2-Positive Metastatic Breast Cancer: Trastuzumab beyond Progression or Lapatinib? A Population Based Cohort Study | |
| 摘 要： | |
| 收稿时间： | 2015-06-25 |
|
||||||||||
|
||||||||||
|
||||||||||
|
|
|
|
| 设为首页 | 免责声明 | 关于勤云 | 加入收藏 |
|
Copyright©北京勤云科技发展有限公司 京ICP备09084417号-23 |
